Tuesday, April 10, 2012

Docetaxel patent, Goodbye!


Well, one of the best anticancer drugs is no more IP protected. I personally worked with this drug – excellent chemical, physical, pharmacological properties. I wish it would be more this type of drug on the market. Now it is available for everybody!
"Taxotere, the successor to the cancer drug Taxol, generated 922 million euros ($1.2 billion) last year for Paris-based Sanofi. That’s a 57 percent drop from the year before because of generic-drug competition, Sanofi said"

No comments:

Post a Comment